secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001680367-24-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027
--------------------------------------------------------------------------------

- Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).
- Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.
- Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.
- Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.
- R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/0001680367-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000050/sttk-20241114.htm
  HTML page:      https://secwatch.observer/filing/0001680367-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer